Our Commitment to Safety Communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.

More than 70,000 patients with RMS or PPMS have started ocrelizumab globally.1

The following ocrelizumab global safety updates are available. Click below to learn more: 

Updated Safety Analysis 

Additional Topics of Interest

Post-marketing Commitments

Indication:

Indications vary in different countries. Please contact your local Roche Affiliate for more information on ocrelizumab.

References

  1. Roche data on file.  October 2018

All Countries

Select a Country

Australia

Brazil

Domincan Republic

Finland

Germany

Kuwait

Norway

Qatar

Sweden

Switzerland / Lichtenstein

Turkey

United Arab Emirates

Australia

Roche Products Pty Limited
Level 8, 30-34 Hickson Road
Sydney NSW 2000 Australia

Tel: +61 2 9454 9444
+61 29454 90002
Fax: +61 2 9971 7401

australia.drug_safety@roche.com
download PI

Brazil

Produtos Roche Químicos e Farmacêuticos S.A.
Av. Engenheiro Billings, 1729
05321-900 São Paulo

Tel: +0800-7720-289 (Call Center)

brasil.faleconosco@roche.com
download PI

Domincan Republic

Productos Roche Dominicana S.R.L.
Av. Winston Churchill Esq.
Paseo de los Locutores Plaza las Americas II
Local Y 28 B
Santo Domingo, D.N.

cac.farmacovigilancia@roche.com (Costa Rica sub-region)
download PI

Finland

Roche Oy
Klovinpellontie 3, PO Box 12
02180 Espoo
Finland

Tel: + 358 10 554 500

finland.laaketurva@roche.com
download PI

Germany

Roche Pharma AG
Emil-Barell-Str. 1
79639 Grenzach-Wyhlen

Tel: +497624 14 2869

grenzach.drug_safety@roche.com
download SmPC

Kuwait

Gulf Safety Unit
Cairo Festival City, Business Park A, Building A2, 4th Floor, Fifth Settlement 
11835, Cairo, Egypt

Mobile: +20 1271400006

gulf.safety@roche.com
download PI

Norway

Roche Norge AS Brynsengfaret
6 B, 0667 Oslo
Postboks 6610
Etterstad, 0607 Oslo

Tel: +47 22789000

norway.drug_safety@roche.com
pharma.norge@roche.com
View SmPC

Qatar

Gulf Safety Unit
Cairo Festival City, Business Park A, Building A2, 4th Floor, Fifth Settlement
11835, Cairo, Egypt

Mobile: +20 1271400006

gulf.safety@roche.com
download PI

Sweden

Roche AB Box 1228
S-171 23 Solna

Tel: + 46 (0) 8 726 12 00
Fax: + 46 (0) 8 744 06 81

sverige.safety@roche.com
view SmPC

Switzerland / Lichtenstein

Roche Pharma (Schweiz) AG
Schoenmattstr. 2
4153 Reinach

Fax: +41 61 815 28 45

switzerland.ds@roche.com
download PI_de
download PI_fr

Turkey

Uniq İstanbul, Ayazağa Cad. No.4
D/101
Maslak 34396 Sarıyer-İstanbul

Tel: +90 212 366 90 00

istanbul.adversolay@roche.com
download SPC

United Arab Emirates

Medical Department Hoffmann-La Roche Ltd. 
Galleries Buildings NO4, Floor 5, Jabel Ali Downtown
P.O. Box 27309
Dubai, UAE

Tel: +971 48164895
Mobile: +971 (0)54 440 9415
Fax: +971 4 8800212

dubai.drug_safety@roche.com
download PI